Browse by Research Team

2024

Passenger gene coamplifications create collateral therapeutic vulnerabilities in cancer.
Bei, Y. and Brame, Luca and Kirchner, M. and Fritsche-Guenther, R. and Kunz, S. and Bhattacharya, A. and Rusu, M.C. and Gürgen, D. and Dubois, F.P.B. and Köppke, J.K.C. and Proba, J. and Wittstruck, N. and Sidorova, O.A. and Chamorro González, R. and Dorado Garcia, H. and Brückner, L. and Xu, R. and Giurgiu, M. and Rodriguez-Fos, E. and Yu, Q. and Spanjaard, B. and Koche, R.P, and Schmitt, C.A. and Schulte, J.H. and Eggert, A. and Haase, K. and Kirwan, J. and Hagemann, A.I. and Mertins, P. and Dörr, J.R. and Henssen, A.G.
Cancer Discovery 14 (3): 492-507. 1 March 2024

2021

Germline mutations including the rare pathogenic variant c.3206delC in the ATM gene cause ataxia teleangiectasia-associated primary central nervous system lymphoma.
Dörr, J.R. and Thorwarth, A. and Mizia-Malarz, A. and Radke, J. and Tietze, A. and Hernáiz-Driever, P. and Horn, D. and Gratopp, A. and Eggert, A. and Deubzer, H.E.
Children 8 (6): 469. June 2021

2020

H3K9me3-mediated epigenetic regulation of senescence in mice predicts outcome of lymphoma patients.
Schleich, K. and Kase, J. and Dörr, J.R. and Trescher, S. and Bhattacharya, A. and Yu, Y. and Wailes, E.M. and Fan, D.N.Y. and Lohneis, P. and Milanovic, M. and Lau, A. and Lenze, D. and Hummel, M. and Chapuy, B. and Leser, U. and Reimann, M. and Lee, S. and Schmitt, C.A.
Nature Communications 11 (1): 3651. 20 July 2020

2018

Senescence-associated reprogramming promotes cancer stemness.
Milanovic, M. and Fan, D.N.Y. and Belenki, D. and Däbritz, J.H.M. and Zhao, Z. and Yu, Y. and Dörr, J.R. and Dimitrova, L. and Lenze, D. and Monteiro Barbosa, I.A. and Mendoza-Parra, M.A. and Kanashova, T. and Metzner, M. and Pardon, K. and Reimann, M. and Trumpp, A. and Dörken, B. and Zuber, J. and Gronemeyer, H. and Hummel, M. and Dittmar, G. and Lee, S. and Schmitt, C.A.
Nature 553 (7686): 96-100. 4 January 2018

2016

CD20-targeting immunotherapy promotes cellular senescence in B-cell lymphoma.
Däbritz, J.H.M. and Yu, Y. and Milanovic, M. and Schönlein, M. and Rosenfeldt, M.T. and Dörr, J.R. and Kaufmann, A.M. and Dörken, B. and Schmitt, C.A.
Molecular Cancer Therapeutics 15 (5): 1074-1081. May 2016

2013

Synthetic lethal metabolic targeting of cellular senescence in cancer therapy.
Dörr, J.R. and Yu, Y. and Milanovic, M. and Beuster, G. and Zasada, C. and Däbritz, J.H.M. and Lisec, J. and Lenze, D. and Gerhardt, A. and Schleicher, K. and Kratzat, S. and Purfürst, B. and Walenta, S. and Mueller-Klieser, W. and Gräler, M. and Hummel, M. and Keller, U. and Buck, A.K. and Dörken, B. and Willmitzer, L. and Reimann, M. and Kempa, S. and Lee, S. and Schmitt, C.A.
Nature 501 (7467): 421-425. 19 September 2013

2011

Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations.
Jing, H. and Kase, J. and Dörr, J.R. and Milanovic, M. and Lenze, D. and Grau, M. and Beuster, G. and Ji, S. and Reimann, M. and Lenz, P. and Hummel, M. and Doerken, B. and Lenz, G. and Scheidereit, C. and Schmitt, C.A. and Lee, S.
Genes & Development 25 (20): 2137-2146. 15 October 2011

2010

Tumor stroma-derived TGF-beta limits Myc-driven lymphomagenesis via Suv39h1-dependent senescence.
Reimann, M. and Lee, S. and Loddenkemper, C. and Dörr, J.R. and Tabor, V. and Aichele, P. and Stein, H. and Doerken, B. and Jenuwein, T. and Schmitt, C.A.
Cancer Cell 17 (3): 262-272. 16 March 2010